Found: 23
Select item for more details and to access through your institution.
Preclinical development of siRNA therapeutics for AL amyloidosis.
- Published in:
- Gene Therapy, 2011, v. 18, n. 12, p. 1150, doi. 10.1038/gt.2011.69
- By:
- Publication type:
- Article
A conversation with Donald Seldin. Interview by Ushma Neill.
- Published in:
- 2012
- By:
- Publication type:
- Biography
An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
- Published in:
- Bone Marrow Transplantation, 2001, v. 28, n. 7, p. 637, doi. 10.1038/sj.bmt.1703200
- By:
- Publication type:
- Article
Familial vitamin D-resistant rickets. Study of six cases with evaluation of the pathogenetic role of secondary hyperparathyroidism.
- Published in:
- 1968
- By:
- Publication type:
- journal article
Symposium on acid-base homeostasis. The generation and maintenance of metabolic alkalosis.
- Published in:
- 1972
- By:
- Publication type:
- journal article
Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis.
- Published in:
- Bone Marrow Transplantation, 2015, v. 50, n. 6, p. 868, doi. 10.1038/bmt.2015.9
- By:
- Publication type:
- Article
Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.
- Published in:
- Bone Marrow Transplantation, 2014, v. 49, n. 10, p. 1345, doi. 10.1038/bmt.2014.132
- By:
- Publication type:
- Article
Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
- Published in:
- Bone Marrow Transplantation, 2014, v. 49, n. 3, p. 434, doi. 10.1038/bmt.2013.192
- By:
- Publication type:
- Article
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
- Published in:
- Bone Marrow Transplantation, 2013, v. 48, n. 12, p. 1537, doi. 10.1038/bmt.2013.98
- By:
- Publication type:
- Article
A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.
- Published in:
- Bone Marrow Transplantation, 2011, v. 46, n. 7, p. 976, doi. 10.1038/bmt.2010.239
- By:
- Publication type:
- Article
Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction.
- Published in:
- Bone Marrow Transplantation, 2010, v. 45, n. 1, p. 21, doi. 10.1038/bmt.2009.94
- By:
- Publication type:
- Article
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
- Published in:
- 2007
- By:
- Publication type:
- Correction Notice
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
- Published in:
- Bone Marrow Transplantation, 2007, v. 40, n. 6, p. 557, doi. 10.1038/sj.bmt.1705746
- By:
- Publication type:
- Article
Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation.
- Published in:
- Bone Marrow Transplantation, 2006, v. 38, n. 5, p. 339, doi. 10.1038/sj.bmt.1705447
- By:
- Publication type:
- Article
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
- Published in:
- Bone Marrow Transplantation, 2005, v. 36, n. 7, p. 597, doi. 10.1038/sj.bmt.1705106
- By:
- Publication type:
- Article
Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
- Published in:
- Bone Marrow Transplantation, 2005, v. 35, n. 6, p. 567, doi. 10.1038/sj.bmt.1704826
- By:
- Publication type:
- Article
Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
- Published in:
- 2005
- By:
- Publication type:
- Correction Notice
High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
- Published in:
- Bone Marrow Transplantation, 2004, v. 33, n. 4, p. 381, doi. 10.1038/sj.bmt.1704346
- By:
- Publication type:
- Article
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 11, p. 2317, doi. 10.1038/leu.2012.100
- By:
- Publication type:
- Article
CK2 and its role in Wnt and NF-κB signaling: Linking development and cancer.
- Published in:
- Cellular & Molecular Life Sciences, 2009, v. 66, n. 11/12, p. 1850, doi. 10.1007/s00018-009-9153-z
- By:
- Publication type:
- Article
Skin reactions associated with oral revlimid (lenalidomide) in AL amyloidosis (ALA); patient teaching encouraging prompt reporting, and clinical assessment and management of skin reactions can impact patient outcomes.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article